Supplementary Table III. Patient characteristics (three or more metastatic organs).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | All (n = 48) | IO-IO (n = 38) | IO-TKI (n = 10) | *p*-Value |
| Follow-up duration, months, median (IQR) | | 11.3 (5.3–27.6) | 11.5 (4.7–26.6) | 9.8 (5.5–40.9) | 0.73 |
| Age, years, median (IQR) | | 68 (63–71) | 68 (63–71) | 68 (65–70) | 0.58 |
| Sex, N (%) | |  |  |  | 0.55 |
|  | Male | 37 (77.1) | 31 (79.0) | 7 (70.0) |  |
|  | Female | 11 (22.9) | 7 (21.0) | 3 (30.0) |  |
| IMDC, N (%) | |  |  |  | 0.19 |
|  | Intermediate | 20 (41.7) | 14 (36.8) | 6 (60.0) |  |
|  | Poor | 28 (58.3) | 24 (63.2) | 4 (40.0) |  |
| Subtype, N (%) | |  |  |  | 0.52 |
|  | Clear | 40 (83.3) | 31 (81.6) | 9 (90.0) |  |
|  | non-clear/undetectable | 8 (16.7) | 7 (18.4) | 1 (10.0) |  |
| 1st-line treatment, N (%) | |  |  |  |  |
|  | Nivolumab + Ipilimumab | 38 (79.2) | 38 (100) | 0 |  |
|  | Avelumab + Axitinib | 2 (4.2) | 0 | 2 (20.0) |  |
|  | Pembrolizumab + Axitinib | 2 (4.2) | 0 | 2 (20.0) |  |
|  | Nivolumab + Cabozantinib | 3 (6.2) | 0 | 3 (30.0) |  |
|  | Pembrolizumab + Lenvatinib | 3 (6.2) | 0 | 3 (30.0) |  |
| Prior nephrectomy, N (%) | |  |  |  | 0.50 |
|  | Yes | 15 (31.2) | 11 (28.9) | 4 (40.0) |  |
|  | No | 33 (68.8) | 27 (71.1) | 6 (60.0) |  |
| Number of metastatic organs, N (%) | |  |  |  | 0.08 |
|  | 3 | 29 (60.4) | 26 (68.4) | 3 (30.0) |  |
|  | 4 | 10 (20.8) | 6 (15.8) | 4 (40.0) |  |
|  | ≥5 | 9 (18.8) | 6 (15.8) | 3 (30.0) |  |
| Metastatic organ sites at baseline | |  |  |  |  |
|  | Lung | 43 (89.6) | 34 (89.5) | 9 (90.0) | 0.96 |
|  | Liver | 17 (35.4) | 12 (31.6) | 5 (50.0) | 0.28 |
|  | Lymph node | 33 (68.8) | 26 (68.4) | 7 (70.0) | 0.92 |
|  | Bone | 25 (52.1) | 21 (55.3) | 4 (40.0) | 0.39 |
|  | Brain | 11 (22.9) | 8 (21.1) | 3 (30.0) | 0.55 |
|  | Pancreas | 12 (25.0) | 9 (23.7) | 3 (30.0) | 0.68 |
|  | Others | 33 (68.8) | 24 (63.2) | 9 (90.0) | 0.10 |

Abbreviations: N, number; IO, immune-oncologic drug; TKI, tyrosine kinase inhibitor; IQR, interquartile range; IMDC, international metastatic renal cell carcinoma database consortium